The Full Story in Plain English
What the Study Found (In Plain English)
Why This Matters to You
Ipragliflozin (ASP1941) is a selective sodium glucose cotransporter 2 inhibitor in clinical development for the treatment of patients with type 2 diabetes (T2DM). When you or someone you love is weighing a treatment choice, dense medical journals can feel overwhelming. Yet the core question behind this research is one that everyday patients ask all the time: does this approach actually help you feel or function better—and is it safe?
How the Study Worked
To find out, researchers writing in Clinical therapeutics conducted a randomized controlled trial evaluating 18 real-world participants. Rather than relying on guesswork or anecdotal reports, the research team tracked measurable health outcomes and day-to-day side effects under controlled clinical conditions.
What the Study Found in Plain English
Combination treatment for 14 days with ipragliflozin and metformin was well tolerated in patients withT2DM without low blood sugar. The addition of ipragliflozin (300 mg qd) to metformin therapy did not result in a clinically relevant change in the PK properties of metformin. ClinicalTrials.gov identifier: NCT01302145. Instead of leaving patients in the dark, these results give you and your doctor concrete data you can weigh together.
The Catch: What to Keep in Mind
Even strong medical studies have limits. Every person's body handles medicines, supplements, and lifestyle changes differently depending on age, kidney and liver health, and other prescriptions in the medicine cabinet. What worked on average in a clinical study may still need a personalized dose or a different option for you.
Bottom Line: Your Next Step
Bring this summary to your next doctor or pharmacist visit. Ask: "Based on my health history and current medications, does this research apply to me?" You can also click the formal study link below to inspect the original peer-reviewed paper directly.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Published in Clinical therapeutics (2012-08-15) • Study Design: Randomized Controlled Trial • Participants: N = 18 • Biostatistical Rigor Score: 88/100. Primary Takeaway: Combination treatment for 14 days with ipragliflozin and metformin was well tolerated in patients withT2DM without low blood sugar.
Study Limitations & Caveats Before You Act
While this randomized controlled trial scored 88/100 for research quality, clinical trials follow strict rules that may not match every patient's daily life. Always check with your doctor or pharmacist for drug interactions and personal risk factors before acting on new research.
Formal Peer-Reviewed Study Reference
“Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus”
Published in Clinical therapeutics (2012-08-15) • PMID/ID: 22795925